Night Vision Disturbances Market to Experience Accelerated Development by 2034

Strategic Insights -

Night Vision Disturbances refer to difficulties or impairments in seeing clearly in low-light or nighttime conditions. This condition can be caused by various factors, including aging, underlying health issues such as cataracts, retinal diseases, or conditions like vitamin A deficiency. Individuals with NVD often experience reduced visual acuity, glare, halos, or difficulty adjusting to darkness, which can impact daily activities such as driving at night or navigating low-light environments.

As the market for Night Vision Disturbances treatments continues to grow, several key factors are driving its development. The aging population, growing awareness of the condition, technological advancements, increased research and development, and rising prevalence of retinal diseases are all contributing to the rapid expansion of the Night Vision Disturbances market. Emerging therapies, such as Phentolamine Ophthalmic Solution 0.75% (Nyxol), are being developed to address the condition, and the market is expected to surge due to its increasing prevalence and awareness during the forecast period.

Key Takeaways:

  • The Night Vision Disturbances market size is anticipated to grow with a significant CAGR during the study period (2020-2034).
  • In 2023, the Night Vision Disturbance (NVD) market, including supportive care, was valued at USD 3,216 million across the 7MM.
  • The US held the largest market size for Night Vision Disturbance (NVD) among the 7MM, with an estimated USD 1,754 million in 2023.
  • The market size for Night Vision Disturbance (NVD) in Japan was estimated to be approximately USD 434 million in 2023.
  • The total diagnosed prevalent cases of Night Vision Disturbance (NVD) across the 7MM reached nearly 55 million in 2023.
  • The Night Vision Disturbances market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period.
  • The market is expected to experience accelerated development through 2034, with several emerging therapies being developed to address the condition.
  • Phentolamine Ophthalmic Solution 0.75% (Nyxol) is one of the emerging therapies being developed to treat Night Vision Disturbances.
  • The Night Vision Disturbances market is expected to be driven by factors such as aging population, growing awareness, technological advancements, increased research and development, and rising prevalence of retinal diseases.

Statistics:

  • The Night Vision Disturbances market size is anticipated to grow with a significant CAGR of 1.08% during the study period (2020-2034).
  • The total diagnosed prevalent cases of Night Vision Disturbance (NVD) across the 7MM reached nearly 55 million in 2023.
  • The US accounted for the largest share of total diagnosed prevalent cases of Night Vision Disturbance (NVD), representing 44% in 2023.
  • Japan reported nearly 9 million diagnosed prevalent cases of Night Vision Disturbance (NVD) in 2023, representing about 16% of the total cases across the 7MM.

Sources:

  • DelveInsight's "Night Vision Disturbances Market Insights, Epidemiology, and Market Forecast-2034'' report.
  • M2 PRESSWIRE-October 20, 2025-: Night Vision Disturbances Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Ocuphire Pharma, Viatris (C)1994-2025 M2 COMMUNICATIONS RDATE:17102025.